Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Here’s What’s Bugging Us: Multi-Drug Resistance and Beta-Lactam Pharmacokinetics

Dr. Mena Lora and Scheetz

Speakers:
Alfredo J. Mena Lora, MD, FACP
Clinical Assistant Professor in the Department of Medicine
Medical Director of Infection Control at Saint Anthony Hospital
Program Director, Infectious Diseases Fellowship
Associate Program Director, Internal Medicine Residency

and

Marc H. Scheetz, PharmD, MSc, FCCP, FCP
Professor, Midwestern University
College of Pharmacy Downers Grove, Department of Pharmacy Practice
College of Graduate Studies, Department of Pharmacology
College of Graduate Studies, Department of Biomedical Sciences
Director, Pharmacometrics Center of Excellence
Infectious Diseases Pharmacist, Northwestern Medicine, Department of Pharmacy

A Knowledge-Based Activity
ACPE UAN # 0016-0000-23-030-L01-P, 1.0 contact hour, 1.0 AMA PRA Category 1 Credit(s)™ CME, 1.0 contact hour CNE

Learning Objectives:

  • Review the current state of the evidence for treatment of multidrug resistant organisms in the ICU.
  • Identify the best antimicrobials for the treatment of severe bloodstream infections and pneumonias in the ICU.
  • Review the national and international uptake of beta-lactam monitoring.
  • Describe variability in beta-lactam exposure seen in intensive care patients and define population dosing and precision dosing.

Speaker Disclosures

Dr. Marc Scheetz, a speaker, is a consultant for DoseMe, AbbVie; Chambless, Higdon, Richardson, Katz & Griggs, LLP; Cidara; F2G; Guidepoint Global Consulting; Hall, Booth, Smith P.C.; Merck; Nevakar; Reminger Co., L.P.A; Spero; SuperTrans; Takeda; Taylor, English, Duma, LLP; and Third Pole Therapeutics. Dr. Scheetz has received honoraria from St. Jude and ASHP and was a grant investigator for Allecra, Cystic Fibrosis Foundation, and the NIH. Dr. Scheetz is the owner of patent US10688195B2. All other speakers, planning committee members, and reviewers who contributed to this activity have no relevant financial relationships with ineligible companies to disclose.